Search company, investor...

Predict your next investment

Venture Capital
FINANCE | Investment Firms & Funds
visionaryvc.com

Investments

26

Portfolio Exits

4

Funds

3

About Visionary Venture Fund

Visionary Venture Fund is a venture capital firm that invests in the most promising emerging ophthalmology companies. With many breakthrough ophthalmic technologies and platforms on the horizon, Visionary Venture Fund was created to help these companies by contributing clinical expertise, commercialization know-how, and growth capital.

Headquarters Location

75 Enterprise

Aliso Viejo, California, 92656,

United States

310-694-6847

Are you an investor?
Submit your portfolio details now to be considered in our investor rankings.

Latest Visionary Venture Fund News

From one eye whisperer to another: A decade in review

Nov 7, 2022

Disclosures: Jackson reports consulting for Alcon, Allergan/AbbVie, Bausch + Lomb, Bruder, Carl Zeiss Meditec, EyePoint Pharmaceuticals, Johnson & Johnson, Lensar, Novartis, Ocular Therapeutix, Ocuphire, Rayner/Omeros, RxSight, ScienceBased Health, Sight Sciences, Sun Pharmaceuticals, Trukera, Versea and Visus and being a shareholder in Ace Vision Group, Calhoun Vision, Excelerate Health Fund, Lenticular Research Group, Myze, Ocuphire, Paragon, RPS and Visionary Venture Fund II. ADD TOPIC TO EMAIL ALERTS Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . Please try again later. If you continue to have this issue please contact customerservice@slackinc.com . Back to Healio I would like to congratulate Mitch Jackson on his 100th Premium Channel column in OSN. Mitch’s entertaining approach to presenting cutting-edge techniques and technology in premium refractive surgery has always matched his ebullient personality. Richard L. Lindstrom, MD Source: Healio As premium surgeons, we frequently pass information to one another to better our outcomes, business practices and/or our self-beings as persons as well as surgeons. The term “whisperer,” as in the games “Chinese whispers” or “telephone,” involves the passing of information, but it gets slightly changed each time going from one person to another. In 2011, I started a column called the Fine Art of Premium IOLs in Premier Surgeon, a sister publication to Ocular Surgery News, which carried into 2013, when my first Premium Channel column ran in the practice management section of OSN. Now, we have reached my 100th Premium Channel installment. Mitchell A. Jackson Information has been passed from this one premium surgeon to all my premium surgeon colleagues, but the times have changed and so has the information for the most part, at least in terms of clinical and therapeutic applications. You can scan the accompanying QR code to access my Premium Channel columns, but I am going to highlight my 20 favorite ones — two from each year over the past 10 years. 1. Solving the ‘-osin’ mystery  (June 10, 2013) — Thorough preoperative planning is key in avoiding potential IFIS-related complications during and after cataract surgery. 4. Top five fact vs. fiction analysis of femtosecond laser cataract surgery  (Dec. 10, 2014) — Dispelling myths may help the premium surgeon decide on whether to add a laser to his or her armamentarium. 5. Does [pupil] size matter? How premium surgeons can avoid the inevitable  (Aug. 10, 2015) — When a pupil is at least 5.25 mm or greater at the start of the procedure, the main goal is to prevent intraoperative progressive miosis as the case proceeds. 6. ‘Talking heads’ act as guardians of patient care  (Nov. 10, 2015) — These key opinion leaders help improve the lives of patients and fellow practitioners. 7. A little microburst goes a long way  (Oct. 10, 2016) — Microburst phaco techniques in conjunction with femtosecond laser-assisted cataract surgery can result in faster surgery with less ultrasound power. 8. 2016 year in review: Miracles do happen  (Jan. 10, 2017) — Looking ahead, anticipated approvals for new devices and pharmaceuticals would benefit patients and physicians in 2017. 9. Are bacteria getting smarter? (July 10, 2017) — The premium surgeon has to be prepared to combat bacterial resistance. The beauty of being able to put down my editorial and personal perspective as a premium surgeon for my colleagues, industry and friends has been quite rewarding this past decade. I want to thank the entire Healio/Ocular Surgery News team for all its work to make this Premium Channel column a reality, allowing the “eye whispering” to continue through the years. I look forward to continue bringing my perspective quarterly, with my next column looking back at the top 10 industry moments of 2022. Stay safe and healthy, and thanks to all my followers who read this column. For more information: Mitchell A. Jackson, MD, can be reached at Jacksoneye, 300 N. Milwaukee Ave., Suite L, Lake Villa, IL 60046; email: mjlaserdoc@msn.com . Read more about

Visionary Venture Fund Investments

26 Investments

Visionary Venture Fund has made 26 investments. Their latest investment was in TearClear as part of their Series C on July 7, 2023.

CBI Logo

Visionary Venture Fund Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

7/11/2023

Series C

TearClear

$11.76M

No

1

3/8/2023

Series C

ONL Therapeutics

$15M

Yes

2

12/29/2022

Series A - II

Amydis

$6M

Yes

1

11/30/2022

Series A

Subscribe to see more

$99M

Subscribe to see more

10

8/9/2022

Series B

Subscribe to see more

$99M

Subscribe to see more

10

Date

7/11/2023

3/8/2023

12/29/2022

11/30/2022

8/9/2022

Round

Series C

Series C

Series A - II

Series A

Series B

Company

TearClear

ONL Therapeutics

Amydis

Subscribe to see more

Subscribe to see more

Amount

$11.76M

$15M

$6M

$99M

$99M

New?

No

Yes

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

1

2

1

10

10

Visionary Venture Fund Portfolio Exits

4 Portfolio Exits

Visionary Venture Fund has 4 portfolio exits. Their latest portfolio exit was RxSight on July 30, 2021.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

7/30/2021

IPO

$99M

Public

2

10/16/2020

IPO

Subscribe to see more

$99M

Subscribe to see more

10

12/19/2018

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

10/23/2018

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

Date

7/30/2021

10/16/2020

12/19/2018

10/23/2018

Exit

IPO

IPO

Acquired

Acquired

Companies

Subscribe to see more

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

Acquirer

Public

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

2

10

10

10

Visionary Venture Fund Fund History

3 Fund Histories

Visionary Venture Fund has 3 funds, including Visionary Venture Fund II (QP).

Closing Date

Fund

Fund Type

Status

Amount

Sources

6/28/2019

Visionary Venture Fund II (QP)

$46.6M

1

6/28/2019

Visionary Venture Fund II

$99M

10

5/2/2017

Visionary Venture Fund

Subscribe to see more

Subscribe to see more

$99M

10

Closing Date

6/28/2019

6/28/2019

5/2/2017

Fund

Visionary Venture Fund II (QP)

Visionary Venture Fund II

Visionary Venture Fund

Fund Type

Subscribe to see more

Status

Subscribe to see more

Amount

$46.6M

$99M

$99M

Sources

1

10

10

Visionary Venture Fund Team

2 Team Members

Visionary Venture Fund has 2 team members, including current Founder, Chief Investment Officer, Managing Partner, Jeffry Weinhuff.

Name

Work History

Title

Status

Jeffry Weinhuff

Founder, Chief Investment Officer, Managing Partner

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Name

Jeffry Weinhuff

Subscribe to see more

Work History

Title

Founder, Chief Investment Officer, Managing Partner

Subscribe to see more

Status

Current

Subscribe to see more

Compare Visionary Venture Fund to Competitors

L
Laureate Pharma

Laureate Pharma is a company focused on the healthcare and pharmaceutical industry. It provides a range of services including the synthesis of pharmaceutical substances, the creation of finished dosage forms, and the development and launch of pulmonary drugs. The company primarily sells to the healthcare sector, with a focus on pharmacies and other pharmaceutical companies. It is based in Princeton, New Jersey.

Blaze Systems Logo
Blaze Systems

Blaze Systems is a provider of total LIMS software solutions for the laboratory marketplace.

T
The Liposome Company

The Liposome Company is developing liposome-based drug delivery

K
Kryosphere

Kryosphere provides customized biorepository, logistical, and clinical sample management services to companies with a critical biospecimen component. Kryosphere delivers secure, scalable solutions to customers ranging from small, emerging entities to large corporations worldwide.

C
Critical Pharmaceuticals

Critical Pharmaceuticals is an advanced drug delivery company with core expertise in delivery of macromolecules such as DNA, proteins, peptides, siRNA and aptamers.

C
Cytogel

Cytogel, Inc., is working on the development of promising drug candidates and drug delivery technologies

Loading...

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.